KVA12123, along with Merck’s KEYTRUDA, is intended for the treatment of advanced solid tumours Credit: SciPro/Shutterstock.com.

Kineta has dosed the first patient in Part B of the Phase I/II VISTA-101 clinical trial evaluating KVA12123, along with Merck & Co (MSD)’s anti-PD-1 therapy Keytruda (pembrolizumab), in treating advanced solid tumours.

The dose escalation and dose expansion, multicentre, open-label study will assess the immunogenicity, pharmacokinetics (PK), tolerability, safety, and tumour response of KVA12123, alone and along with pembrolizumab.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Part B is part of the dose escalation study that also includes Part A, and the goal is to determine a recommended Phase II dose (RP2D) for Parts C and D.

Parts C and D will focus on the dose expansion of VISTA-101 as a single-agent and in combination with pembrolizumab.

Part A included six cohorts, which received KVA12123 monotherapy while Part B comprises four cohorts that will receive the combination therapy of KVA12123 and pembrolizumab.

One to six participants in each cohort will receive their respective dosages to characterise the pharmacodynamics, PK, tolerability, safety, and preliminary tumour responses of study interventions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In preclinical models, through the combination of unique epitope binding and an optimised IgG1 Fc region, KVA12123 demonstrated strong monotherapy tumour growth inhibition, without evidence of cytokine release syndrome in study participants.

It also effectively de-risks the VISTA target and provides a new approach to addressing immune suppression in the tumour microenvironment.

Kineta claims that KVA12123 also has the potential to treat colorectal, head and neck, non-small cell lung, and ovarian cancers, as well as renal cell carcinoma.

Initial combination therapy and additional monotherapy safety and efficacy data are expected in the second quarter of next year.

Kineta CEO Shawn Iadonato said: “We anticipate that the results from the combination arm will further build on the already encouraging initial safety, tolerability, and pharmacokinetic profile of KVA12123 observed in the monotherapy arm.

“We look forward to reporting initial clinical data for the combination treatment next year.”